Olaparib
Sources
publication, as of 2026-11-07
https://pmc.ncbi.nlm.nih.gov/articles/PMC11157627/
OLAGLI: olaparib in recurrent IDH-mutant high-grade glioma, POLA Network Phase 2 (NCT03561870), PMC11157627 (search record)
Brief source I14
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT03561870
A Phase II Study of Olaparib in Recurrent IDH-mutant High Grade Gliomas OLAGLI
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT03991832
A Phase II Study of Olaparib and Durvalumab (MEDI 4736) in Patients With IDH-Mutated Solid Tumors
ClinicalTrials.gov API v2 record, retrieved 2026-11-07
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05188508
A Phase II Study of Pembrolizumab, Olaparib, and Temozolomide in Patients With Glioma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07